UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 100

Sortiert nach

Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis

Annals of oncology, 2023-02, Vol.34 (2), p.173-185

2023

Volltextzugriff (PDF)

Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial

ESMO open, 2023-12, Vol.8 (6), p.102065-102065, Article 102065

2023

Volltextzugriff (PDF)

Platinum-based chemotherapy versus monotherapy in first-line treatment of elderly patients with advanced non-small-cell lung cancer

Journal of geriatric oncology, 2014-10, Vol.5, p.S37-S37

2014

Volltextzugriff (PDF)

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

The New England journal of medicine, 2018-05, Vol.378 (22), p.2093-2104

2018

Volltextzugriff (PDF)

EGFR tyrosine kinase inhibitors in first-line treatment of elderly patients with advanced non-small-cell lung cancer

Journal of geriatric oncology, 2014-10, Vol.5, p.S33-S34

2014

Volltextzugriff (PDF)

591P The utility of next generation sequencing for KRAS gene variants prevalence in cytological and tissue samples in real-world NSCLC patients: A large single institution real-world study

Annals of oncology, 2023-11, Vol.34, p.S1701

2023

Volltextzugriff (PDF)

1394P Real-world experience in treatment of patients with non-small cell lung cancer with BRAF and cMET Exon 14 skipping mutations

Annals of oncology, 2023-10, Vol.34, p.S798-S799

2023

Volltextzugriff (PDF)

1485P Systemic inflammatory index dynamics at 6 weeks as an early surrogate for clinical benefit in patients with NSCLC and PD-L1≥50% expression treated with pembrolizumab: Data from the real-life practice

Annals of oncology, 2023-10, Vol.34, p.S839-S839

2023

Volltextzugriff (PDF)

1244P Real-world EGFR and T790M testing patterns in patients from Central Eastern Europe with advanced non-small cell lung cancer: Results from a large retrospective study (REFLECT)

Annals of oncology, 2021-09, Vol.32, p.S980-S980

2021

Volltextzugriff (PDF)

1228P Real-world treatment patterns and clinical outcomes in patients from Central Eastern Europe with EGFR-mutated advanced non-small cell lung cancer: Results from a large retrospective study (REFLECT)

Annals of oncology, 2021-09, Vol.32, p.S973-S974

2021

Volltextzugriff (PDF)

1683P SARS-CoV-2 infection and lung cancer management in Europe

Annals of oncology, 2020-09, Vol.31, p.S996-S997

2020

Volltextzugriff (PDF)

1299P Real-world treatment patterns, clinical outcomes and EGFR/T790M testing practices in patients with EGFRm advanced NSCLC and 1L EGFR TKI therapy: A retrospective multinational study (REFLECT)

Annals of oncology, 2020-09, Vol.31, p.S840-S840

2020

Volltextzugriff (PDF)

EP08.02-159 Post Hoc Analyses of Dacomitinib-Associated Skin Disorders and Efficacy in the ARCHER 1050 Study

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S480-S482

2022

Volltextzugriff (PDF)

P37.09 Comparison of 3 Different Methods for Determination of EGFR p.Thr790Met mutation in patients with NSCLC

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S445-S446

2021

Volltextzugriff (PDF)

P37.02 Identification of Gene Fusions and Mutations in Patients with NSCLC using two Diagnostic Approaches: Rapid qPCR and NGS

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S442-S442

2021

Volltextzugriff (PDF)

P78.08 Prediction of Pembrolizumab Efficacy in Non-Small-Cell Lung Cancer (NSCLC) Based on Experience From Expanded Access Program in Poland

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S641-S641

2021

Volltextzugriff (PDF)

HSD57 The Actionable Gaps of the Journey of Patients With Lung Cancer

Value in health, 2022-12, Vol.25 (12), p.S284-S284

2022

Volltextzugriff (PDF)

P2.06-09 Association of Clinical Response and HRQoL with Long-Term Survival with 1L Nivolumab + Ipilimumab in mNSCLC in CheckMate 227

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S320-S321

2023

Volltextzugriff (PDF)

OA14.03 Six-year Survival and HRQoL Outcomes with 1L Nivolumab + Ipilimumab in Patients with Metastatic NSCLC from CheckMate227

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S76-S77

2023

Volltextzugriff (PDF)

41P Efficacy of first-line (1L) nivolumab (N) + ipilimumab (I) by tumor histologic subtype in patients (pts) with metastatic nonsquamous NSCLC (mNSQ-NSCLC)

Journal of thoracic oncology, 2023-04, Vol.18 (4), p.S64-S65

2023

Volltextzugriff (PDF)

122MO Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment (tx) for patients (pts) with advanced NSCLC (aNSCLC) and baseline (BL) brain metastases (mets): Intracranial and systemic outcomes from CheckMate 227 Part 1

Annals of oncology, 2021-12, Vol.32, p.S1430-S1431

2021

Volltextzugriff (PDF)

4O Nivolumab (NIVO) + ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced NSCLC (aNSCLC) in CheckMate 227 part 1: Efficacy by KRAS, STK11, and KEAP1 mutation status

Annals of oncology, 2021-12, Vol.32, p.S1375-S1376

2021

Volltextzugriff (PDF)

P76.67 Safety and Efficacy of First-Line Dacomitinib in Advanced Non-Small Cell Lung Cancer by EGFR Mutation SUBtype in ARCHER 1050

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S617-S618

2021

Volltextzugriff (PDF)

LBA3 Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (aNSCLC): CheckMate 227 - part 2 final analysis

Annals of oncology, 2019-12, Vol.30, p.xi67-xi68

2019

Volltextzugriff (PDF)

Updated overall survival (OS) from extended follow up in ARCHER 1050: A randomized phase III study comparing dacomitinib with gefitinib as first-line therapy for patients (pts) with EGFR mutations

Annals of oncology, 2019-11, Vol.30, p.ix200-ix201

2019

Volltextzugriff (PDF)

1 – 25 von 100

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(93)
Mit Volltextzugriff
(94)

Publikationsform

Artikel
(99)
Berichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(33)
Science & Technology
(33)
Oncology
(29)
Humans
(19)
Lung Cancer
(15)
Patients
(15)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(14)
Chemotherapy
(12)
Metastasis
(12)
Mutation
(12)
Cancer Therapies
(11)
Immunotherapy
(11)
Lung Neoplasms - Drug Therapy
(11)
Female
(10)
Male
(10)
Adult
(9)
Carcinoma, Non-Small-Cell Lung - Genetics
(9)
Aged
(8)
Lung Neoplasms - Genetics
(8)
Middle Aged
(8)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis

Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial

Platinum-based chemotherapy versus monotherapy in first-line treatment of elderly patients with advanced non-small-cell lung cancer

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

EGFR tyrosine kinase inhibitors in first-line treatment of elderly patients with advanced non-small-cell lung cancer

591P The utility of next generation sequencing for KRAS gene variants prevalence in cytological and tissue samples in real-world NSCLC patients: A large single institution real-world study

1394P Real-world experience in treatment of patients with non-small cell lung cancer with BRAF and cMET Exon 14 skipping mutations

1485P Systemic inflammatory index dynamics at 6 weeks as an early surrogate for clinical benefit in patients with NSCLC and PD-L1≥50% expression treated with pembrolizumab: Data from the real-life practice

1244P Real-world EGFR and T790M testing patterns in patients from Central Eastern Europe with advanced non-small cell lung cancer: Results from a large retrospective study (REFLECT)

1228P Real-world treatment patterns and clinical outcomes in patients from Central Eastern Europe with EGFR-mutated advanced non-small cell lung cancer: Results from a large retrospective study (REFLECT)

1683P SARS-CoV-2 infection and lung cancer management in Europe

1299P Real-world treatment patterns, clinical outcomes and EGFR/T790M testing practices in patients with EGFRm advanced NSCLC and 1L EGFR TKI therapy: A retrospective multinational study (REFLECT)

EP08.02-159 Post Hoc Analyses of Dacomitinib-Associated Skin Disorders and Efficacy in the ARCHER 1050 Study

P37.09 Comparison of 3 Different Methods for Determination of EGFR p.Thr790Met mutation in patients with NSCLC

P37.02 Identification of Gene Fusions and Mutations in Patients with NSCLC using two Diagnostic Approaches: Rapid qPCR and NGS

P78.08 Prediction of Pembrolizumab Efficacy in Non-Small-Cell Lung Cancer (NSCLC) Based on Experience From Expanded Access Program in Poland

HSD57 The Actionable Gaps of the Journey of Patients With Lung Cancer

P2.06-09 Association of Clinical Response and HRQoL with Long-Term Survival with 1L Nivolumab + Ipilimumab in mNSCLC in CheckMate 227

OA14.03 Six-year Survival and HRQoL Outcomes with 1L Nivolumab + Ipilimumab in Patients with Metastatic NSCLC from CheckMate227

41P Efficacy of first-line (1L) nivolumab (N) + ipilimumab (I) by tumor histologic subtype in patients (pts) with metastatic nonsquamous NSCLC (mNSQ-NSCLC)

122MO Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment (tx) for patients (pts) with advanced NSCLC (aNSCLC) and baseline (BL) brain metastases (mets): Intracranial and systemic outcomes from CheckMate 227 Part 1

4O Nivolumab (NIVO) + ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced NSCLC (aNSCLC) in CheckMate 227 part 1: Efficacy by KRAS, STK11, and KEAP1 mutation status

P76.67 Safety and Efficacy of First-Line Dacomitinib in Advanced Non-Small Cell Lung Cancer by EGFR Mutation SUBtype in ARCHER 1050

LBA3 Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (aNSCLC): CheckMate 227 - part 2 final analysis

Updated overall survival (OS) from extended follow up in ARCHER 1050: A randomized phase III study comparing dacomitinib with gefitinib as first-line therapy for patients (pts) with EGFR mutations

Suchergebnisse filtern